Association Between Polyp Detection Rate and Post-Colonoscopy Cancer Among Patients Undergoing Diagnostic Colonoscopy

Rachel Gingold-Belfer; Doron Boltin; Orly Sneh-Arbib; Doron Comaneshter; Arnon Cohen; Anath Flugelman; Alex Vilkin; Yaron Niv; Lital Boker Keinan; Iris Dotan; Zohar Levi

doi:10.1016/j.cgh.2019.11.016

Association Between Polyp Detection Rate and Post-Colonoscopy Cancer Among Patients Undergoing Diagnostic Colonoscopy

Rachel Gingold-Belfer
, Doron Boltin
, Orly Sneh-Arbib
, Doron Comaneshter
, Arnon Cohen
, Anath Flugelman
, Alex Vilkin
, Yaron Niv
, Lital Boker Keinan
, Iris Dotan
, Zohar Levi

Tel Aviv University, Ben-Gurion University of the Negev, Technion - Israel Institute of Technology

Research output: Contribution to journal › Short survey › peer-review

Abstract

Postcolonoscopy colorectal cancer (PCCRC) can arise from missed cancers, missed premalignant lesions, incomplete resection, and new cancers with an accelerated route to cancer.¹

Original language	English
Pages (from-to)	202-204
Number of pages	3
Journal	Clinical Gastroenterology and Hepatology
Volume	19
Issue number	1
DOIs	https://doi.org/10.1016/j.cgh.2019.11.016
State	Published - 1 Jan 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1016/j.cgh.2019.11.016

Cite this

Gingold-Belfer, R., Boltin, D., Sneh-Arbib, O., Comaneshter, D., Cohen, A., Flugelman, A., Vilkin, A., Niv, Y., Keinan, L. B., Dotan, I., & Levi, Z. (2021). Association Between Polyp Detection Rate and Post-Colonoscopy Cancer Among Patients Undergoing Diagnostic Colonoscopy. Clinical Gastroenterology and Hepatology, 19(1), 202-204. https://doi.org/10.1016/j.cgh.2019.11.016

@article{a3ac08e67a10440cbfc70416a676f5c0,

title = "Association Between Polyp Detection Rate and Post-Colonoscopy Cancer Among Patients Undergoing Diagnostic Colonoscopy",

abstract = "Postcolonoscopy colorectal cancer (PCCRC) can arise from missed cancers, missed premalignant lesions, incomplete resection, and new cancers with an accelerated route to cancer.1",

author = "Rachel Gingold-Belfer and Doron Boltin and Orly Sneh-Arbib and Doron Comaneshter and Arnon Cohen and Anath Flugelman and Alex Vilkin and Yaron Niv and Keinan, \{Lital Boker\} and Iris Dotan and Zohar Levi",

note = "Funding Information: Conflicts of interest These authors disclose the following: Arnon Cohen received research grants from Janssen, Novartis, AbbVie, Janssen, and Sanofi and served as a consultant, advisor, or speaker to AbbVie, Amgen, Boehringer Ingelheim, Dexcel Pharma, Janssen, Kamedis, Lilly, Neopharm, Novartis, Perrigo, Pfizer, Rafa, Samsung Bioepis, Sanofi, Sirbal, and Taro. Iris Dotan served as a consultant for AbbVie, Janssen, Takeda, Pfizer, Genentech/Roche, Gilead, Rafa, Celltrion, Ferring, and Medtronic and as a speaker for AbbVie, Janssen, Takeda, Pfizer, Genentech/Roche, Ferring, and Falk Pharma. The remaining authors disclose no conflicts. Publisher Copyright: {\textcopyright} 2021 AGA Institute",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/j.cgh.2019.11.016",

language = "English",

volume = "19",

pages = "202--204",

number = "1",

}

Gingold-Belfer, R, Boltin, D, Sneh-Arbib, O, Comaneshter, D, Cohen, A, Flugelman, A, Vilkin, A, Niv, Y, Keinan, LB, Dotan, I & Levi, Z 2021, 'Association Between Polyp Detection Rate and Post-Colonoscopy Cancer Among Patients Undergoing Diagnostic Colonoscopy', Clinical Gastroenterology and Hepatology, vol. 19, no. 1, pp. 202-204. https://doi.org/10.1016/j.cgh.2019.11.016

TY - JOUR

T1 - Association Between Polyp Detection Rate and Post-Colonoscopy Cancer Among Patients Undergoing Diagnostic Colonoscopy

AU - Gingold-Belfer, Rachel

AU - Boltin, Doron

AU - Sneh-Arbib, Orly

AU - Comaneshter, Doron

AU - Cohen, Arnon

AU - Flugelman, Anath

AU - Vilkin, Alex

AU - Niv, Yaron

AU - Keinan, Lital Boker

AU - Dotan, Iris

AU - Levi, Zohar

N1 - Funding Information: Conflicts of interest These authors disclose the following: Arnon Cohen received research grants from Janssen, Novartis, AbbVie, Janssen, and Sanofi and served as a consultant, advisor, or speaker to AbbVie, Amgen, Boehringer Ingelheim, Dexcel Pharma, Janssen, Kamedis, Lilly, Neopharm, Novartis, Perrigo, Pfizer, Rafa, Samsung Bioepis, Sanofi, Sirbal, and Taro. Iris Dotan served as a consultant for AbbVie, Janssen, Takeda, Pfizer, Genentech/Roche, Gilead, Rafa, Celltrion, Ferring, and Medtronic and as a speaker for AbbVie, Janssen, Takeda, Pfizer, Genentech/Roche, Ferring, and Falk Pharma. The remaining authors disclose no conflicts. Publisher Copyright: © 2021 AGA Institute

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Postcolonoscopy colorectal cancer (PCCRC) can arise from missed cancers, missed premalignant lesions, incomplete resection, and new cancers with an accelerated route to cancer.1

AB - Postcolonoscopy colorectal cancer (PCCRC) can arise from missed cancers, missed premalignant lesions, incomplete resection, and new cancers with an accelerated route to cancer.1

UR - https://www.scopus.com/pages/publications/85092604091

U2 - 10.1016/j.cgh.2019.11.016

DO - 10.1016/j.cgh.2019.11.016

M3 - Short survey

C2 - 31712082

SN - 1542-3565

VL - 19

SP - 202

EP - 204

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 1

ER -

Association Between Polyp Detection Rate and Post-Colonoscopy Cancer Among Patients Undergoing Diagnostic Colonoscopy

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this